(RTTNews) – Today’s Daily Dose brings you news of AstraZeneca postponing its Phase 3 of the COVID-19 candidate vaccine, Albireo’s positive knowledge of the Odevixibat Phase 3 trial in progressive family intrahepathic cholestasis, the disappointing effects of Corbus from his Phase 3 Lenabasum trial on diffuse skin Systemic sclerosis, RedHill’s promising “in vitro” knowledge of the candidate drug COVID-19 , tests the effects of ADAPT-PO through spero and Pfizer’s fair investment in Trillium.
Read. . .
1. AstraZeneca suspends COVID-19 vaccine trial
AstraZeneca PLC (AZN) suspended Phase III of its COVID-19 vaccine candidate, AZD1222, after an adverse reaction in a trial participant, Stat News reports.
The United States has recorded 6,326,696 active cases of COVID-19 and 189,639 deaths to date in the Johns Hopkins University database.
AZN closed Tuesday’s consultation at $54. 71, up 2. 11%. In the afternoon, inventory dropped by 8. 14% to $50. 25.
2. Albireo Pharma reaches new heights
The actions of Albireo Pharma Inc. (ALBO) rose 79% to a new 52-week high of $49 in intraday operations on Tuesday, following the positive effects of a phase III global clinical trial of Odevixibat on progressive family intrahepathic cholestasis 1 or 2, to Uncommon Liver Genetic Disease.
The company plans to submit full regulatory applications for Odevixibat for the indication of progressive familial intrahepatic cholestasis in the EU and US until early 2021.
In addition, the company announced that it had introduced a public tender offer of 3 million shares of its usual shares.
ALBO closed on Tuesday at $39. 62, an increase of 44. 76%.
3. Co-diagnosis to expand COVID-19 services
The CO-Diagnostics Logix Smart COVID-19 test, which is CE-marked and legal for emergency use through the FDA, is used for the diagnosis of SARS-CoV-2, the COVID-19 virus, in the United States and many countries. . other countries.
Arches Research has performed co-diagnostic tests for its clients since the beginning of this year.
CODX closed Tuesday at $11. 70, up 41. 99%.
4. Corbus Pharma dives into disappointing results
Systemic sclerosis, a form of scleroderma, is a rare and debilitating chronic autoimmune disease that affects approximately 200,000 other people in North America, the EU and Japan.
The Combined Average Response Index of the American College of Rheumatology for Systemic Sclerosis (ACR CRISS) at week 52, which reflects the probability of patient improvement, is explained as the trial’s number one assessment criterion.
In the Phase III trial, called RESOLVE-1, there were no significant differences in the number one and secondary assessment criteria when comparing Lenabasum with a placebo, either added to fundamental immunosuppressive drugs.
The CRBP closed Tuesday’s consultation at $ 2. 23, down 75. 89%.
RedHill Opaganib is the subject of a global phase 2/3 in patients with severe COVID-19 pneumonia and phase 2 in patients with severe COVID-19 pneumonia in the United States.
RDHL closed Tuesday at $8. 41, an increase of 13. 04%.
6. Spero Therapeutics is based on the effects of the ADAPT-PO trial
In the phase III study, designated ADAPT-PO, oral HBr tebipenem was statistically non-inferior to Merck-approved intravenous (IV) ertapenem for the treatment of patients with cUTI and patients with acute pyelonephritis.
Spero intends to complete the NDA filing for US regulatory approval. But it’s not the first time Tebipenem HBr in the quarter of 2021.
SPRO closed Tuesday’s consultation at $ 13. 07, an increase of 45. 87%. In the afternoon, the name gained 1. 07% to $ 13. 21.
7. Strongbridge Biopharma collapses even though the LOGICS study achieved the key goal
At the end of the retirement phase of the LOGICS study, 54. 5% more patients who were eliminated from placebo had an average reaction loss in loose cortisol in the urine compared to those who remained in RECORLEV, the company noted.
Adverse occasions of specific interest in the LOGICS examination included liver-like, adrenal insufficiency-like, and QT prolongation.
The company plans to submit an application for a new RECORLEV drug to the FDA in the first quarter of 2021.
SBBP closed On Tuesday at $2. 82, down 20. 11%.
Trillium Therapeutics Inc. (TRIL) rose more than 38% after hours on Tuesday following a proposed equitable investment through Pfizer Inc. (PFE) a registered direct offering.
The Company agreed to sell non-unusual 2. 29 million consistent percentages at a value of $ 10. 88 consistent with a consistent percentage to Pfizer for gross proceeds of $ 25. 0 million. The offering is expected to close on or around September 10, 2020.
The main applicants for Trillium come with TTI-621, in a Phase 1 exam in patients with complex relither or refractory malignant liver disease, and TTI-622, which is evaluated in a Phase 1a/1b examination in patients with relither or refractory complex lymphoma or myeloma. .
TRIL closed Tuesday’s consultation at $ 9. 46, down 1. 77%. In long-term operations, inventory was up 38. 48% to $ 13. 10.
SCWorx Corp. (WORX) closed Tuesday’s consultation at $1. 86, up 22. 37%.
Cancer Genetics Inc. (CGIX) closed on Tuesday at $5. 26, an increase of 21. 48%.
TRACON Pharmaceuticals Inc. (TCON) closed Tuesday at $3. 74, an increase of 20. 65%.
Biocept Inc. (BIOC) closed Tuesday’s consultation at $4. 42, down 16. 89%.
Venus Concept Inc. (VERO) closed Tuesday’s consultation at $ 2. 23, down 16. 48%.